 <h1>Polivy Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>polatuzumab vedotin</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about polatuzumab vedotin. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Polivy.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to polatuzumab vedotin: intravenous powder for solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, polatuzumab vedotin (the active ingredient contained in Polivy) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking polatuzumab vedotin:</p><p>
<i>More common</i>
</p><ul>
<li>Back pain</li>
<li>black, tarry stools</li>
<li>bleeding gums</li>
<li>blood in urine or stools</li>
<li>bone pain</li>
<li>burning, numbness, tingling, or painful sensations</li>
<li>chest pain or tightness</li>
<li>confusion</li>
<li>cough or hoarseness</li>
<li>dry mouth</li>
<li>fast or irregular heartbeat</li>
<li>fever or chills</li>
<li>flushing</li>
<li>headache</li>
<li>increased thirst</li>
<li>lightheadedness or fainting</li>
<li>loss of appetite</li>
<li>lower back, side, or stomach pain</li>
<li>mood or mental changes</li>
<li>muscle pain or cramps</li>
<li>nausea or vomiting</li>
<li>numbness or tingling in the mouth, fingers, hands, or feet</li>
<li>painful cold sores or blisters on the lips, nose, eyes, or genitals</li>
<li>painful or difficult urination</li>
<li>pale skin</li>
<li>pinpoint red spots on the skin</li>
<li>seizures</li>
<li>sore throat</li>
<li>sores, ulcers, or white spots on the lips or in the mouth</li>
<li>stomach cramps</li>
<li>swelling of the feet or lower legs</li>
<li>swollen glands</li>
<li>tremor</li>
<li>troubled breathing</li>
<li>ulcers, sores, or white spots in the mouth</li>
<li>unsteadiness or awkwardness</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
<li>weakness in the arms, hands, legs, or feet</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of polatuzumab vedotin may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Body aches or pain</li>
<li>diarrhea</li>
<li>difficulty in moving</li>
<li>dizziness</li>
<li>ear congestion</li>
<li>joint pain</li>
<li>loss of voice</li>
<li>muscle stiffness</li>
<li>runny or stuffy nose</li>
<li>sneezing</li>
<li>weight loss</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Blurred vision</li>
</ul><p>
<!-- end intravenous powder for solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to polatuzumab vedotin: intravenous powder for injection</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Neutropenia (49%), thrombocytopenia (49%), anemia (47%), lymphopenia (13%), febrile neutropenia (11%)</p>
<p><b>Common</b> (1% to 10%): Pancytopenia<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Infections (32%), herpesvirus infection (12%)</p>
<p><b>Common</b> (1% to 10%): Cytomegalovirus infection</p>
<p><b>Uncommon</b> (0.1% to 1%): Progressive multifocal leukoencephalopathy (PML), sepsis</p>
<p><b>Frequency not reported</b>: Immunogenicity<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Infusion-related reactions (e.g., fever, chills, flushing, dyspnea, hypotension, urticaria) (67%)</p>
<p><b>Common</b> (1% to 10%): Infusion-related reactions<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Arthralgia<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Blurred vision<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Anorexia (27%), weight loss (16%), hypokalemia (16%), hypoalbuminemia (13%), hypocalcemia (11%)</p>
<p><b>Common</b> (1% to 10%): Hypophosphatemia</p>
<p><b>Frequency not reported</b>: Tumor lysis syndrome (TLS)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Transaminase elevation<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Dyspnea (19%), upper respiratory tract infection (16%), lower respiratory tract infection (10%)</p>
<p><b>Common</b> (1% to 10%): Pneumonitis<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Pyrexia (33%)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Peripheral neuropathy (40%), dizziness (13%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (38%), vomiting (18%)</p>
<p><b>Common</b> (1% to 10%): Lipase increased<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Polivy (polatuzumab vedotin)." Genentech, South San Francisco, CA. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about Polivy (polatuzumab vedotin)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>Drug class: miscellaneous antineoplastics</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Polivy &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Diffuse Large B-Cell Lymphoma</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to polatuzumab vedotin: intravenous powder for injection</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Neutropenia (49%), thrombocytopenia (49%), anemia (47%), lymphopenia (13%), febrile neutropenia (11%)</p><p><b>Common</b> (1% to 10%): Pancytopenia<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Infections (32%), herpesvirus infection (12%)</p><p><b>Common</b> (1% to 10%): Cytomegalovirus infection</p><p><b>Uncommon</b> (0.1% to 1%): Progressive multifocal leukoencephalopathy (PML), sepsis</p><p><b>Frequency not reported</b>: Immunogenicity<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Infusion-related reactions (e.g., fever, chills, flushing, dyspnea, hypotension, urticaria) (67%)</p><p><b>Common</b> (1% to 10%): Infusion-related reactions<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Arthralgia<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Blurred vision<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Anorexia (27%), weight loss (16%), hypokalemia (16%), hypoalbuminemia (13%), hypocalcemia (11%)</p><p><b>Common</b> (1% to 10%): Hypophosphatemia</p><p><b>Frequency not reported</b>: Tumor lysis syndrome (TLS)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Transaminase elevation<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Dyspnea (19%), upper respiratory tract infection (16%), lower respiratory tract infection (10%)</p><p><b>Common</b> (1% to 10%): Pneumonitis<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Pyrexia (33%)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Peripheral neuropathy (40%), dizziness (13%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (38%), vomiting (18%)</p><p><b>Common</b> (1% to 10%): Lipase increased<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Polivy (polatuzumab vedotin)." Genentech, South San Francisco, CA. </p><h2>More about Polivy (polatuzumab vedotin)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>Drug class: miscellaneous antineoplastics</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Polivy &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Diffuse Large B-Cell Lymphoma</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>